Viz.ai Launches Viz Recruit Software to Speed Clinical Trial Enrollment

January 21, 2021—Viz.ai has announced the launch of the Viz Recruit software that uses artificial intelligence (AI) to accelerate clinical studies.

According to the company, Recruit uses AI to automatically detect a suspected disease (such as a brain hemorrhage, tumor, or cardiac structural abnormality) and uses that insight to ensure the right doctor is notified about the patient.

Additionally, Recruit alerts research teams about potentially eligible trial patients across an entire health system and enables easy communication between clinical teams, research teams, principal investigators, and core labs to facilitate enrollment.

The first industry-sponsored clinical study to use Viz Recruit is the ENRICH trial, which is sponsored by Nico Corporation to investigate minimally invasive hematoma extraction for patients with intracranial hemorrhage. One site in the trial that uses Viz Recruit—the University of Buffalo in Buffalo, New York—enrolled at a rate 3.3 times greater than without the software, noted Viz.ai.

ENRICH investigator Brian Jankowitz, MD, commented in the company’s announcement, “Viz Recruit is how clinical trials should be run. We are able to be alerted to potential patients and quickly move them to enrollment and treatment. I hope we can use Viz Recruit for all of our other clinical studies.” Dr. Jankowitz is a neurosurgeon and Director of Cerebrovascular Program at Cooper University Health Care in Camden, New Jersey.